Phytocannabinoids for Cancer Therapeutics: Recent Updates and Future Prospects

Area of Science:

• Pharmacology and Phytochemistry
• Endocannabinoid System Research
• Oncology Therapeutics

Background:

• Phytocannabinoids (pCBs) are plant-derived compounds with a history in medicine and recreation.
• The discovery of the endocannabinoid system (ECS), a key drug discovery target, was influenced by Cannabis constituents.
• The ECS comprises cannabinoid receptors (CB1, CB2), endocannabinoids (AEA, 2-AG), and metabolizing enzymes (FAAH, MAGL).

Purpose of the Study:

• To review and discuss the potential of phytocannabinoids (pCBs) as novel cancer therapeutics.
• To explore pCBs that target the endocannabinoid system (ECS), focusing on CB2 receptors and metabolizing enzymes.
• To highlight pCBs from non-cannabis sources as safe and effective drug development candidates.

Main Methods:

• Literature review and critical discussion of existing research on phytocannabinoids and the ECS.
• Analysis of studies investigating pCBs' interaction with cannabinoid receptors and metabolizing enzymes.
• Evaluation of pCBs derived from both cannabis and non-cannabis plants for therapeutic potential in cancer.

Main Results:

• Phytocannabinoids (pCBs) interact with cannabinoid receptors (CB1, CB2) and enzymes (FAAH, MAGL) of the ECS.
• pCBs from non-cannabis plants show promise as cancer therapeutics, avoiding the psychotropic effects of CB1 targeting.
• These plant-derived compounds offer a safer, more accessible, and potentially effective approach to cancer drug development.

Conclusions:

• Phytocannabinoids (pCBs) represent a promising class of compounds for developing novel cancer therapeutics.
• Targeting the CB2 receptor or endocannabinoid-metabolizing enzymes with pCBs offers a safer therapeutic strategy.
• Further research into pCBs from diverse plant sources is warranted for advancing cancer treatment.